Answers are grounded in this paper and cite their sources.
Plasmodium vivax is a major cause of malaria in India, especially in the southwest, where chloroquine (CQ) followed by 14-day primaquine is the recommended treatment; however, antimalarial drug resistance poses a significant threat, prompting this study to investigate the molecular epidemiology of drug resistance in vivax malaria clinical samples from southwestern India. A total of 93 P. vivax malaria samples were collected from symptomatic adult patients at three sites in two districts: Kasturba Medical College, Manipal (13/07/2021–30/09/2024), Udupi District Hospital (07/07/2022–30/09/2024), and the Malaria Clinic, Mangaluru District Hospital (07/07/2022–30/09/2024). Extracted DNA was amplified and sequenced for resistance markers, including Pvcrt-o, Pvmdr1, Pvdhfr, and Pvdhps genes using Sanger sequencing, with genetic polymorphisms and haplotypes analyzed for resistance-associated mutations. In Pvcrt-o , the K10 AAG insertion was detected in 26% of samples; Pvmdr1 harbored M908L, T958M, Y976F, and F1076L mutations in 100%, 86.02%, 2.15%, and 84.94% of samples, respectively; Pvdhps showed A383G and A553G in 26.88% and 13.97%; while Pvdhfr exhibited S58R and S117N in 59.13% and 56.98%, with the double mutant (S58R+S117N) as the most prevalent haplotype. While mutations do not indicate complete CQ resistance, the Y976F mutation observed in two samples has been previously associated with reduced chloroquine susceptibility; these findings underscore the need for ongoing molecular surveillance and targeted antimalarial strategies.
No takes yet. Share an insight, caveat, or question.
Nallapati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: